MDR-001 / MindRank AI - LARVOL DELTA

10.3% weight loss in 24 weeks! Deruizhi Pharmaceuticals' AI-designed small molecule GLP-1 receptor agonist MDR-001 was successful in Phase IIb clinical trials [Google translation] (Sohu.com) - P2b | N=300 | NCT06606483 | Sponsor: MindRank AI Ltd | "In this multicenter Phase IIb clinical trial led by Professor Ji Linong of Peking University People's Hospital, 317 overweight or obese subjects participated in the study. The results showed that the average weight loss of subjects treated with MDR-001 tablets was 10.3%. In contrast, the placebo group only lost 2.5%. Such results are not only remarkable, but also bring new hope to obese patients...The results of the study showed that the effectiveness of MDR-001 is not only reflected in weight loss, but also in improving metabolic and cardiovascular disease-related indicators. For example, the subjects' waist circumference, blood lipids, blood pressure and other indicators have been significantly improved. Such comprehensive benefits make MDR-001 a very promising weight loss drug....In terms of safety, MDR-001 performed well. No serious adverse events related to drug treatment occurred during the trial."

P2b data • Obesity

A Phase I/IIa Clinical Study to Assess the Single and Multiple Ascending Doses of MDR-001 Tablets in Healthy Participants and Obese/ Overweight Participants (clinicaltrials.gov) - P1/2 | N=131 | Recruiting | Sponsor: MindRank AI Ltd

New P1/2 trial • Obesity

A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: MindRank AI Ltd

New P2 trial • Genetic Disorders • Obesity